Ingrid Schalij
Overview
Explore the profile of Ingrid Schalij including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
816
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun X, Klouda T, Barnasconi S, Schalij I, Schwab J, Nielsen-Kudsk A, et al.
Am J Physiol Lung Cell Mol Physiol
. 2024 May;
327(2):L250-L257.
PMID: 38810241
In the field of pulmonary hypertension (PH), a well-established protocol to induce severe angioproliferation in rats (SuHx) involves combining the VEGF-R inhibitor Sugen 5416 (SU5416) with 3 wk of hypoxia...
2.
Rotteveel L, Poot A, Kooijman E, Schuit R, Schalij I, Sun X, et al.
EJNMMI Res
. 2023 Mar;
13(1):23.
PMID: 36947258
Transforming growth factor β (TGFβ) activity is perturbed in remodelled pulmonary vasculature of patients with pulmonary arterial hypertension (PAH), cancer, vascular diseases and developmental disorders. Inhibition of TGFβ, which signals...
3.
van der Laarse W, Bogaards S, Schalij I, Vonk Noordegraaf A, Vaz F, van Groen D
J Physiol
. 2022 Aug;
600(20):4465-4484.
PMID: 35993114
Right-sided myocardial mechanical efficiency (work output/metabolic energy input) in pulmonary hypertension can be severely reduced. We determined the contribution of intrinsic myocardial determinants of efficiency using papillary muscle preparations from...
4.
Sanada T, Sun X, Happe C, Guignabert C, Tu L, Schalij I, et al.
Cells
. 2021 Jan;
10(1).
PMID: 33419137
Recent translational studies highlighted the inhibition of transforming growth factor (TGF)-β signaling as a promising target to treat pulmonary arterial hypertension (PAH). However, it remains unclear whether alterations in TGF-β...
5.
Sun X, Peters E, Schalij I, Axelsen J, Andersen S, Kurakula K, et al.
Am J Respir Cell Mol Biol
. 2020 Dec;
64(3):331-343.
PMID: 33264068
Monoamine oxidases (MAOs), a class of enzymes bound to the outer mitochondrial membrane, are important sources of reactive oxygen species. Increased MAO-A activity in endothelial cells and cardiomyocytes contributes to...
6.
de Raaf M, Schalij I, Bogaard H
Hypertens Res
. 2020 Sep;
43(11):1313-1314.
PMID: 32884125
No abstract available.
7.
Gomez-Puerto M, Sun X, Schalij I, Orriols M, Pan X, Szulcek R, et al.
Int J Mol Sci
. 2020 Jun;
21(11).
PMID: 32531895
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by obstructed pulmonary vasculatures. Current therapies for PAH are limited and only alleviate symptoms. Reduced levels of BMPR2 are associated with...
8.
Happe C, Kurakula K, Sun X, Da Silva Goncalves Bos D, Rol N, Guignabert C, et al.
Cells
. 2020 Jun;
9(6).
PMID: 32521690
Mutations in bone morphogenetic protein receptor type II (BMPR2) are leading to the development of hereditary pulmonary arterial hypertension (PAH). In non-hereditary forms of PAH, perturbations in the transforming growth...
9.
Kurakula K, Sun X, Happe C, Da Silva Goncalves Bos D, Szulcek R, Schalij I, et al.
Eur Respir J
. 2019 Jul;
54(3).
PMID: 31273046
Pulmonary arterial hypertension (PAH) is a progressive fatal disease characterised by abnormal remodelling of pulmonary vessels, leading to increased vascular resistance and right ventricle failure. This abnormal vascular remodelling is...
10.
Van Der Feen D, Kurakula K, Tremblay E, Boucherat O, Bossers G, Szulcek R, et al.
Am J Respir Crit Care Med
. 2019 May;
200(7):910-920.
PMID: 31042405
Pulmonary arterial hypertension (PAH) is a degenerative arteriopathy that leads to right ventricular (RV) failure. BRD4 (bromodomain-containing protein 4), a member of the BET (bromodomain and extra-terminal motif) family, has...